The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma
Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the Phase II study (NCT04696055) of regorafenib plus pembrolizumab in patients with hepatocellular carcinoma (HCC), who had previously received at least one checkpoint inhibitor, mostly atezolizumab plus bevacizumab, in the first line. Another cohort of patients had undergone several other treatment regimens. The overall survival (OS) across all patients was quite low, with the OS rates for regorafenib plus pembrolizumab being similar to those typically treated with regorafenib alone followed by sorafenib. Neither treatment group met the primary endpoint of the study. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Athenum Consulting; Boehringer Ingelheim; Cardinal Health; Exelixis; QED Therapeutics; Relay Therapeutics
Research Funding – Agios (Inst); ASLAN Pharmaceuticals (Inst); Basilea (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
